CDK9 inhibitor elicits APC through a synthetic lethal effect in colorectal cancer cells  

作　　者：Tingming Liang Lulu Luo Xinru Xu Yajing Du Xinbing Yang Jiahui Xiao Xiaoyan Huang Huiying Yang Siyu Wang Li Guo 

机构地区：[1]Jiangsu Key Laboratory for Molecular and Medical Biotechnology,School of Life Science,Nanjing Normal University,Nanjing,Jiangsu 210023,China [2]State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM),Nanjing University of Posts & Telecommunications,Nanjing,Jiangsu 210023,China

出　　处：《Genes & Diseases》2025年第1期68-71,共4页基因与疾病(英文)

基　　金：supported by National Natural Science Foundation of China(No.62171236);the key project of social development in Jiangsu Province,China(No.BE2022799);the key projects of Natural Science Research in Universities of Jiangsu Province,China(No.22KJA180006);the Open Research Fund of State Key Laboratory of Bioelectronics,Southeast University(No.SKLB2022-K03);the Priority Academic Program Development of Jiangsu Higher Education Institution(PAPD)(China).

摘　　要：Colorectal cancer(CRC)is a significant global health concern,ranking third in incidence and second in mortality among all cancer-related diseases.1 Therefore,it is imperative to prioritize research efforts focused on CRC prevention and treatment to effectively reduce the associated incidence and mortality rates.Synthetic lethality(SL)refers to the phenomenon in which cells harboring two specific gene mutations simultaneously undergo cell death,whereas cells with a single mutation in either of the genes can survive normally.SL strategies are widely concerned in personalized cancer treatment,with the application of PARP inhibitors marking a significant milestone.

关 键 词：MORTALITY PREVENTION TREATMENT 

分 类 号：R735.34[医药卫生—肿瘤]